|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans显示文摘AIM:To assess the risk of biliary and pancreatic cancers in a large cohort of patients with type 2 diabetes mellitus(DM) .METHODS:Eligibility for this study included patients with type 2 DM(ICD-9 code 250.0) who were discharged from Department of Veteran Affairs hospitals between 1990 and 2000.Non-matched control patients without DM were selected from the same patient treatment files during the same period.Demographic information included age,sex and race.Secondary diagnoses included known risk factors based on their ICD-9 codes.By multivariate logistic regression,the occurrence of biliary and pancreatic cancer was compared between case subjects with DM and controls without DM.RESULTS:A total of 1172496 case and control subjects were analyzed.The mean age for study and control subjects was 65.8 ± 11.3 and 64.8 ± 12.6 years,respectively.The frequency of pancreatic cancer in subjects with DM was increased(0.9%) in comparison to control subjects(0.3%) with an OR of 3.22(95% CI:3.03-3.42) .The incidence of gallbladder andextrahepatic biliary cancers was increased by twofold in diabetic patients when compared to controls.The OR and 95% CI were 2.20(1.56-3.00) and 2.10(1.61-2.53) ,respectively.CONCLUSION:Our study demonstrated that patients with DM have a threefold increased risk for developing pancreatic cancer and a twofold risk for developing biliary cancer. | M Mazen Jamal Eugene J Yoon Kenneth J Vega Mehrtash Hashemzadeh Kenneth J Chang | 2009 | World Journal of Gastroenterology2009，15，42： | 10 |
| 2 | Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions显示文摘During the last 15 years we have witnessed an unprecedented expansion in the drugs developed to target human epidermal growth factor receptor-2(HER-2) positive breast cancer. Trastuzumab, pertuzumab, adotrastuzumab emtansine and lapatinib are currently food and drug administration(FDA)-approved for the treatment of breast cancer patients with HER-2 overexpressed. However, given the amount of information gathered from years of uninterrupted clinical research, it is essential to have periodic updates that succinctly recapitulate what we have learnt over these last years and help us to apply that information in our daily practice. This review will pursue that objective. We will summarize the most relevant and updated informationrelated to the state of the art management of HER-2 positive breast cancer in all the clinical scenarios including the adjuvant, neoadjuvant and metastatic settings. But we will also critically appraise that literature in order to highlight some key clinical concepts that should not be overlooked. Lastly, this review will also point out some of the most promising strategies that are currently being tested and may soon become available. | Gonzalo Recondo Jr Enrique Dìaz Canton Màximo de la Vega Martin Greco Gonzalo Recondo Sr Matias E Valsecchi | 2014 | World Journal of Clinical Oncology2014，5，3： | 7 |
| 3 | Fecal immunochemical test accuracy in average-risk colorectal cancer screening显示文摘AIM:To assess the fecal immunochemical test(FIT)accuracy for colorectal cancer(CRC)and advanced neoplasia(AN)detection in CRC screening.METHODS:We performed a multicentric,prospective,double blind study of diagnostic tests on asymptomatic average-risk individuals submitted to screening colonoscopy.Two stool samples were collected and the fecal hemoglobin concentration was determined in the first sample(FIT1)and the highest level of both samples(FITmax)using the OC-sensor.Areas under the curve(AUC)for CRC and AN were calculated.The best FIT1and FITmax cut-off values for CRC were determined.At this threshold,number needed to scope(NNS)to detect a CRC and an AN and the cost per lesion detected were calculated.RESULTS:About 779 individuals were included.An AN was found in 97(12.5%)individuals:a CRC in 5(0.6%)and an advanced adenoma(≥10 mm,villous histology or high grade dysplasia)in 92(11.9%)subjects.For CRC diagnosis,FIT1 AUC was 0.96(95%CI:0.95-0.98)and FITmax AUC was 0.95(95%CI:0.93-0.97).For AN,FIT1 and FITmax AUC were similar(0.72,95%CI:0.66-0.78 vs 0.73,95%CI:0.68-0.79,respectively,P=0.34).Depending on the number of determinations and the positivity threshold cut-off used sensitivity for AN detection ranged between 28%and 42%and specificity between 91%and 97%.At the best cut-off point for CRC detection(115 ng/mL),the NNS to detect a CRC were 10.2 and 15.8;and the cost per CRC was 1814€and 2985€on FIT1 and FITmax strategies respectively.At this threshold the sensitivity,NNS and cost per AN detected were 30%,1.76,and 306€,in FIT1 strategy,and 36%,2.26€and 426€,in FITmax strategy,respectively.CONCLUSION:Performing two tests does not improve diagnostic accuracy,but increases cost and NNS to detect a lesion. | Vicent Hernandez Joaquin Cubiella M Carmen Gonzalez-Mao Felipe Iglesias Concepción Rivera M Begoa Iglesias Lucía Cid Ines Castro Luisa de Castro Pablo Vega Jose Antonio Hermo Ramiro Macenlle Alfonso Martínez-Turnes David Martínez-Ares Pamela Estevez Estela Cid M Carmen Vidal Angeles López-Martínez Elisabeth Hijona Marta Herreros-Villanueva Luis Bujanda Jose Ignacio Rodriguez-Prada the COLONPREV study investigators | 2014 | World Journal of Gastroenterology2014，20，4： | 4 |
| 4 | Comparison of reflux esophagitis and its complications between African Americans and non-Hispanic whites显示文摘AIM: To determine the effect of ethnicity on the severity of reflux esophagitis (RE) and its complications. METHODS: A retrospective search of the endoscopy database at the University of Florida Health Science Center/Jacksonville for all cases of reflux esophagitis and its complications from January 1 to March 31, 2001 was performed. Inclusion criteria were endoscopic evidence of esophagitis using the LA classif ication, reflux related complications and self-reported ethnicity. The data obtained included esophagitis grade, presence of a hiatal hernia, esophageal ulcer, stricture and Barrett's esophagus, and endoscopy indication. RESULTS: The search identified 259 patients with RE or its complications, of which 171 were non-Hispanic whites and 88 were African Americans. The mean ages and male/female ratios were similar in the two groups. RE grade, esophageal ulcer, stricture and hiatal hernia frequency were likewise similar in the groups. Barrett's esophagus was present more often in non-Hispanic whites than in African Americans (15.8% vs 4.5%; P < 0.01). Heartburn was a more frequent indication for endoscopy in non-Hispanic whites with erosive esophagitis than in African Americans (28.1% vs 7.9%; P < 0.001). CONCLUSION: Distribution of RE grade and frequency of reflux-related esophageal ulcer, stricture andhiatal hernia are similar in non-Hispanic whites and African Americans. Heartburn was more frequently and nausea/vomiting less frequently reported as the primary endoscopic indication in non-Hispanic whites compared with African Americans with erosive esophagitis or its complications. African Americans have a decreased prevalence of Barrett's esophagus compared with non-Hispanic whites. | Kenneth J Vega Sian Chisholm M Mazen Jamal | 2009 | World Journal of Gastroenterology2009，15，23： | 4 |
| 5 | Advances and new perspectives in the treatment of metastatic colon cancer显示文摘During the last decade we have witnessed an unprec-edented outburst of new treatment approaches for the management of metastatic colon cancer.Anti-angio-genic drugs,epidermal growth factor receptor blockers and multi-kinase inhibitors have all resulted in small but consistent improvement in clinical outcomes.However,this progress has paradoxically leaded us into new chal-lenges.In many cases the clinical development was done in parallel and the lack of head-to-head compari-son evolved into circumstances where several valid new'standards of care'are available.Even though desir-able in essence,the availability of many options as well as different possible combinations frequently leaves the busy clinician in the difficult situation of having to choose between one or the other,sometimes without solid evidence to support each decision.In addition,progress never stops and new agents are continuously tested.For these reason this review will try to summa-rize all the clinical trials that constitute the theoretical framework that support our daily practice but will also procure the reader with rational answers to common clinical dilemmas by critically appraising the current literature.Lastly,we will provide with a compilation of promising new agents that may soon become our next line of defense against this deadly disease. | Gonzalo Recondo Jr Enrique Díaz-Cantón Máximo de la Vega Martin Greco Gonzalo Recondo Sr Matias E Valsecchi | 2014 | World Journal of Gastrointestinal Oncology2014，6，7： | 2 |
| 6 | Impact of Capsule Endoscopy Findings in the Management of Crohn’s Disease显示文摘 | Vicente Lorenzo-Zú?iga Vicente Moreno Vega Eugeni Domènech Eduard Cabré Míriam Ma?osa Jaume Boix | 2010 | Digestive Diseases and Sciences2010，，2： | 2 |
| 7 | Heavy metal sorption and desorption capacity of soils containing endogenous contaminants 显示文摘 | COVELO E F VEGA F A ANDRADE M L | 2007 | Journal of Hazardous Materials2007，143，： | 1 |
| 8 | Diabetes mellitus following cisplatin treatment显示文摘 | Nan DN Femandez-Ayala M Vega Villegas ME | 2003 | Acha Oncol2003，42，1： | 1 |
| 9 | Depot-specific differences in adipose tissue gene expression in lean and obese subjects显示文摘 | LEFEBVRE A M LAVILLE M VEGA N | 1998 | Diabetes1998，47，1： | 1 |
| 10 | High throughput production, screening and analysis of adeno-associated viral vectors显示文摘 | Drittanti L Rivet C Manceau P Danos O Vega M | 2000 | Gene Ther2000，7，： | 1 |
| 11 | Stress proteins induced by arsenic 显示文摘 | Del Razo L M QuintaniUa - Vega B Brambila - Colom- bres E | 2001 | Toxicology and Applied Pharmacology2001，177，2： | 1 |
| 12 | Perform ance of a LiBr-water absorption chiller operating with plate heat exchangers 显示文摘 | M de Vega J A Almendros-Iba flez G Ruiz | 2006 | Energy Conversion and Management2006，47，： | 1 |
| 13 | Current imaging modalities in the diagnosis of cervical cancer显示文摘 | Jiménez de la M Martínez de Vega Fernández V Recio Rodríguez M | 2008 | Gynecol Oncol2008，110，3： | 1 |
| 14 | Causes of high blood cholesterol显示文摘 | Grundy S M Vega G L | 1990 | Circulation1990，81，2： | 1 |
| 15 | First report of bacterial blight caused by Pseudomonas viridiflava on pea in Spain显示文摘 | Martin-Sanz A Palomo J L Perez de la Vega M | 2010 | Plant Disease2010，94，1： | 1 |
| 16 | Pseudopolarographic de- termination of stability constants of labile zinc complexes in fresh water 显示文摘 | Vega M Pardo R Herguedas M M | 1995 | Analytica Chimica Acta1995，310，1： | 1 |
| 17 | Differential effects of trivalent and pentavalent arsenicalson cell proliferation and cytokine secretion in normal human epidermal keratinocytes显示文摘 | Vega L Styblo M Patterson R | 2001 | Toxicol Appl Pharmaco2001，172，3： | 1 |
| 18 | Influence of the structure on the electrochemical performance of lithium transition metal phosphates as cathode materials in rechargeable lithium batteries : A new high - pressure form of LiMPO4(M =Fe and Ni)显示文摘 | Garci'A - Martin O Alvarez - Vega M Garcia - Alvarado F | 2001 | Chem Mater2001，13，： | 1 |
| 19 | Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells 显示文摘 | Styblo M Del Razo L M Vega L | 2000 | Ar- chives of Toxicology2000，74，6： | 1 |
| 20 | The NO TRAIL to YES TRAIL in cancer therapy (review) 显示文摘 | Lee JY Huerta-Yepez S Vega M | 2007 | Int J Oncol2007，31，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员